Pricing Log in Create free account

argenex SE (ARGX) vs Revolution Medicines, Inc. (RVMD)

argenex SE and Revolution Medicines, Inc. are both Biotechnology companies. argenex SE is the larger, with a market value of $56.3B against $38.1B — 1.5× the size. Revolution Medicines, Inc. has negative trailing earnings, so its P/E is not meaningful; argenex SE trades at 29.8×. Revolution Medicines, Inc. grew revenue faster over the last twelve months: 491.1% against 60.8%. argenex SE has the higher net margin (31.7% vs −894.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, argenex SE leads on 13 and Revolution Medicines, Inc. on 3.

Valuation

Metric ARGX RVMD Biotechnology median
P/E 29.82 n/m 10.26
P/S 9.52 184.79 9.18
P/B 6.71 16.09 2.05
Price to free cash flow 40.96 n/m 24.81
EV/EBITDA 30.39 n/m 0.65
EV/Sales 8.92 172.29 8.98
Earnings yield 3.35% (5.07%) (34.89%)
Free cash flow yield 2.44% (3.73%) (24.52%)

Profitability

Metric ARGX RVMD Biotechnology median
Gross margin 90.21% 95.62% 65.16%
Operating margin 29.34% (805.75%) 0.00%
Net margin 31.68% (894.40%) 0.00%
Free cash flow margin 0.00% (688.93%) 0.00%
Return on equity 0.00% (93.56%) (50.12%)
Return on assets 0.00% (57.07%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARGX RVMD Biotechnology median
Revenue growth (TTM) 60.84% 491.12% 6.26%
EPS growth (last fiscal year) 53.13% (66.20%) 29.88%
Revenue growth, 5-year CAGR 130.77% (10.50%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARGX RVMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.12 8.36 4.89
Net debt to EBITDA (3.23) 1.47 1.01

Dividend

Metric ARGX RVMD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ARGX RVMD Biotechnology median
Market cap 56.27b 38.08b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack